Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of IPI-493 in Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>/=18 years old~* ECOG 0-1~* confirmed hematological malignancy~* refractory to available therapy or for which no therapy is available~* adequate hepatic, renal function~Exclusion Criteria:~* active CNS malignancy~* prolonged QT interval~* significant GI/liver disease~* other serious concurrent illness or medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPI-493 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).